Nasdaq Gdtc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq gdtc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Gdtc Today - Breaking & Trending Today
CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) was the recipient of a large growth in short interest in April. As of April 15th, there was short interest totalling 39,400 shares, a growth of 11.6% from the March 31st total of 35,300 shares. Based on an average trading volume of 25,100 shares, the short-interest ratio […] ....
Shares of CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) were down 1.1% during mid-day trading on Thursday . The stock traded as low as $3.43 and last traded at $3.50. Approximately 88,720 shares were traded during trading, an increase of 131% from the average daily volume of 38,405 shares. The stock had previously closed […] ....
CytoMed Therapeutics Limited (NASDAQ:GDTC – Get Free Report) saw a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 4,800 shares, a drop of 20.0% from the September 30th total of 6,000 shares. Approximately 0.1% of the shares of the company are sold short. Based […] ....
CytoMed Therapeutics’ (NASDAQ:GDTC – Get Free Report) lock-up period will end on Wednesday, October 11th. CytoMed Therapeutics had issued 2,412,369 shares in its public offering on April 14th. The total size of the offering was $9,649,476 based on an initial share price of $4.00. After the end of CytoMed Therapeutics’ lock-up period, restrictions preventing company […] ....
CytoMed Therapeutics’ (NASDAQ:GDTC – Get Free Report) lock-up period is set to end on Wednesday, October 11th. CytoMed Therapeutics had issued 2,412,369 shares in its initial public offering on April 14th. The total size of the offering was $9,649,476 based on an initial share price of $4.00. After the end of CytoMed Therapeutics’ lock-up period, […] ....